Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice

Byung Cheon Lee, Mi Y. Jung, Dae Ho Cho, InSug O-Sullivan, Edward P. Cohen, Tae Sung Kim

Research output: Contribution to journalArticle

Abstract

This study describes the immunotherapeutic properties of vaccines that encode tumor-associated calcium signal transducer-1 (Trop-1), a newly identified breast cancer antigen, in mice with breast cancer. Previously we found that Trop-1 was over-expressed in cellular breast cancer vaccines that were highly enriched for cells that induced therapeutic CTL-mediated immune responses in mice with breast cancer, as compared with non-enriched vaccines. In this study, to determine if the expression of Trop-1 by cells in the enriched vaccine was responsible for its therapeutic benefits, an expression plasmid that specified the Trop-1 gene was transfected into the LM fibroblast cells, which was then used as a vaccine. To augment their immunogenic properties, the fibroblasts were genetically modified before Trop-1 DNA-transfer to secrete IL-2 and to express allogeneic MHC class I H-2Kb-determinants. Mice with established breast cancer treated solely by immunization with fibroblasts modified to express Trop-1 developed CD8+ cell-mediated immunity to the breast cancer cells. The immunity was sufficient to prolong the survival of mice with established breast cancer. In some instances, the immunity was sufficient to result in rejection of the tumor; the mice remained tumor free more than 60 days.

Original languageEnglish
Pages (from-to)7757-7763
Number of pages7
JournalVaccine
Volume28
Issue number49
DOIs
Publication statusPublished - 2010 Nov 16

Fingerprint

breast neoplasms
Immunity
immunity
Breast Neoplasms
antigens
Antigens
mice
Growth
vaccines
fibroblasts
Cancer Vaccines
Vaccines
Fibroblasts
neoplasms
transfer DNA
therapeutics
interleukin-2
Transducers
Cellular Immunity
cell-mediated immunity

Keywords

  • Breast cancer
  • Immunity
  • Trop-1
  • Tumor antigen
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice. / Lee, Byung Cheon; Jung, Mi Y.; Cho, Dae Ho; O-Sullivan, InSug; Cohen, Edward P.; Kim, Tae Sung.

In: Vaccine, Vol. 28, No. 49, 16.11.2010, p. 7757-7763.

Research output: Contribution to journalArticle

@article{5eb31c98f693463282f9861f025eaee6,
title = "Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice",
abstract = "This study describes the immunotherapeutic properties of vaccines that encode tumor-associated calcium signal transducer-1 (Trop-1), a newly identified breast cancer antigen, in mice with breast cancer. Previously we found that Trop-1 was over-expressed in cellular breast cancer vaccines that were highly enriched for cells that induced therapeutic CTL-mediated immune responses in mice with breast cancer, as compared with non-enriched vaccines. In this study, to determine if the expression of Trop-1 by cells in the enriched vaccine was responsible for its therapeutic benefits, an expression plasmid that specified the Trop-1 gene was transfected into the LM fibroblast cells, which was then used as a vaccine. To augment their immunogenic properties, the fibroblasts were genetically modified before Trop-1 DNA-transfer to secrete IL-2 and to express allogeneic MHC class I H-2Kb-determinants. Mice with established breast cancer treated solely by immunization with fibroblasts modified to express Trop-1 developed CD8+ cell-mediated immunity to the breast cancer cells. The immunity was sufficient to prolong the survival of mice with established breast cancer. In some instances, the immunity was sufficient to result in rejection of the tumor; the mice remained tumor free more than 60 days.",
keywords = "Breast cancer, Immunity, Trop-1, Tumor antigen, Vaccination",
author = "Lee, {Byung Cheon} and Jung, {Mi Y.} and Cho, {Dae Ho} and InSug O-Sullivan and Cohen, {Edward P.} and Kim, {Tae Sung}",
year = "2010",
month = "11",
day = "16",
doi = "10.1016/j.vaccine.2010.09.057",
language = "English",
volume = "28",
pages = "7757--7763",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "49",

}

TY - JOUR

T1 - Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice

AU - Lee, Byung Cheon

AU - Jung, Mi Y.

AU - Cho, Dae Ho

AU - O-Sullivan, InSug

AU - Cohen, Edward P.

AU - Kim, Tae Sung

PY - 2010/11/16

Y1 - 2010/11/16

N2 - This study describes the immunotherapeutic properties of vaccines that encode tumor-associated calcium signal transducer-1 (Trop-1), a newly identified breast cancer antigen, in mice with breast cancer. Previously we found that Trop-1 was over-expressed in cellular breast cancer vaccines that were highly enriched for cells that induced therapeutic CTL-mediated immune responses in mice with breast cancer, as compared with non-enriched vaccines. In this study, to determine if the expression of Trop-1 by cells in the enriched vaccine was responsible for its therapeutic benefits, an expression plasmid that specified the Trop-1 gene was transfected into the LM fibroblast cells, which was then used as a vaccine. To augment their immunogenic properties, the fibroblasts were genetically modified before Trop-1 DNA-transfer to secrete IL-2 and to express allogeneic MHC class I H-2Kb-determinants. Mice with established breast cancer treated solely by immunization with fibroblasts modified to express Trop-1 developed CD8+ cell-mediated immunity to the breast cancer cells. The immunity was sufficient to prolong the survival of mice with established breast cancer. In some instances, the immunity was sufficient to result in rejection of the tumor; the mice remained tumor free more than 60 days.

AB - This study describes the immunotherapeutic properties of vaccines that encode tumor-associated calcium signal transducer-1 (Trop-1), a newly identified breast cancer antigen, in mice with breast cancer. Previously we found that Trop-1 was over-expressed in cellular breast cancer vaccines that were highly enriched for cells that induced therapeutic CTL-mediated immune responses in mice with breast cancer, as compared with non-enriched vaccines. In this study, to determine if the expression of Trop-1 by cells in the enriched vaccine was responsible for its therapeutic benefits, an expression plasmid that specified the Trop-1 gene was transfected into the LM fibroblast cells, which was then used as a vaccine. To augment their immunogenic properties, the fibroblasts were genetically modified before Trop-1 DNA-transfer to secrete IL-2 and to express allogeneic MHC class I H-2Kb-determinants. Mice with established breast cancer treated solely by immunization with fibroblasts modified to express Trop-1 developed CD8+ cell-mediated immunity to the breast cancer cells. The immunity was sufficient to prolong the survival of mice with established breast cancer. In some instances, the immunity was sufficient to result in rejection of the tumor; the mice remained tumor free more than 60 days.

KW - Breast cancer

KW - Immunity

KW - Trop-1

KW - Tumor antigen

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=78349310570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349310570&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.09.057

DO - 10.1016/j.vaccine.2010.09.057

M3 - Article

C2 - 20887831

AN - SCOPUS:78349310570

VL - 28

SP - 7757

EP - 7763

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 49

ER -